Clinical Trial to Evaluate the Safety and Immunogenicity of Hiltonol, Poly-ICLC-adjuvanted CD40.HIVRI.Env (VRIPRO) in Adult Participants Who Previously Participated in HVTN 706
NCT06665646
This study is recruiting at 4 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The clinical schedule will consist of 3 injections of CD40.HIVRI.Env (VRIPRO) at weeks 0, 4, and 24.40 volunteers without HIV and in overall good health, aged 18 to 60 years, who previously participated in the HVTN 706 trial.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV Infections
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 1
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- Last updated on ClinicalTrials.gov
- September 18, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- Bridge HIV CRS · San Francisco, CA
Massachusetts · 1
- Brigham and Women's Hospital Vaccine CRS (BWH VCRS) · Boston, MA
Pennsylvania · 1
- Penn Prevention CRS (Site ID# 30310) · Philadelphia, PA
Tennessee · 1
- Vanderbilt Vaccine (VV) CRS · Nashville, TN
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.